CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report

Q: What is Alejandra Carvajal’s role at CytomX Therapeutics (CTMX) in this Form 3?

Alejandra Carvajal is identified as an officer of CytomX Therapeutics, serving as Chief Legal Officer . This officer status makes her a reporting person for insider ownership under the Form 3 disclosure requirements.

Q: What does Exhibit 24.1 in the CytomX (CTMX) Form 3 represent?

Exhibit 24.1 is described as a Power of Attorney . This document authorizes designated persons to act on Alejandra Carvajal’s behalf in connection with required insider ownership and related regulatory filings for CytomX securities.

Q: Are any derivative securities reported in the CytomX (CTMX) Form 3 for Alejandra Carvajal?

No. The derivative section shows no derivative transactions and the derivative position summary is empty. The transaction summary also reports zero derivative transaction count and zero derivative shares for this Form 3.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CytomX Therapeutics, Inc. reports that its Chief Legal Officer, Alejandra Carvajal, has become a reporting insider by filing a Form 3 insider ownership report. No transactions in CytomX securities are reported in this filing, and an attached Exhibit 24.1 provides a Power of Attorney for future Section 16-related actions.

Key Figures

Buy transactions reported: 0 Sell transactions reported: 0 Gift transactions reported: 0 +1 more

4 metrics

Buy transactions reported 0 Number of purchase transactions reported in this Form 3

Sell transactions reported 0 Number of sale transactions reported in this Form 3

Gift transactions reported 0 Number of gift transactions reported in this Form 3

Derivative transactions reported 0 Number of derivative transactions reported in this Form 3

Key Terms

Power of Attorney, reporting person, Form 3

3 terms

Power of Attorney regulatory

"Remarks reference Exhibit 24.1 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

reporting person regulatory

"Reporting person listed as an officer and Chief Legal Officer"

Form 3 regulatory

"Form 3 insider ownership report for CytomX Therapeutics, Inc."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

Available on EDGAR 08/05/2026 - 07:32 PM Accepted by SEC EDGAR 08/05/2026 - 07:32 PM

FAQ

What does CytomX Therapeutics (CTMX) disclose in Alejandra Carvajal’s Form 3?

CytomX discloses that Chief Legal Officer Alejandra Carvajal is now a reporting insider by filing a Form 3. The report shows no transactions in CytomX securities and references an attached Power of Attorney as Exhibit 24.1.

Does the CytomX (CTMX) Form 3 for Alejandra Carvajal show any stock purchases or sales?

No. The Form 3 for CytomX Chief Legal Officer Alejandra Carvajal reports no purchase, sale, gift, or derivative transactions. All transaction-related counts in the summary fields are zero for this filing.

What is Alejandra Carvajal’s role at CytomX Therapeutics (CTMX) in this Form 3?

Alejandra Carvajal is identified as an officer of CytomX Therapeutics, serving as Chief Legal Officer. This officer status makes her a reporting person for insider ownership under the Form 3 disclosure requirements.

What does Exhibit 24.1 in the CytomX (CTMX) Form 3 represent?

Exhibit 24.1 is described as a Power of Attorney. This document authorizes designated persons to act on Alejandra Carvajal’s behalf in connection with required insider ownership and related regulatory filings for CytomX securities.

Are any derivative securities reported in the CytomX (CTMX) Form 3 for Alejandra Carvajal?

No. The derivative section shows no derivative transactions and the derivative position summary is empty. The transaction summary also reports zero derivative transaction count and zero derivative shares for this Form 3.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Carvajal Alejandra

(Last)

(First)

(Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Christopher Ogden, as Attorney-in-Fact for Alejandra Carvajal	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR